Abstract | BACKGROUND: METHODS: RESULTS: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p <0.05). In univariate Cox proportional hazard analysis, the AA genotype was significantly related to a better outcome in nondiabetic patients (hazard ratio: 0.47, 95% CI: 0.20-0.96; p <0.05). No association was found with adverse events in diabetic subjects. After allowance for potential confounders, the AA genotype remained a significant prognostic factor in the nondiabetic group (adjusted HR: 0.41, 95% CI: 0.17-0.94, p <0.05). CONCLUSIONS: The -374T/A RAGE polymorphism is an independent protective factor for cardiac events in nondiabetic patients with CAD. The effect of this genetic variant seems to be attenuated in diabetics, who have chronic RAGE upregulation.
|
Authors | Colomba Falcone, Diego Geroldi, Maria P Buzzi, Enzo Emanuele, Yusuf Yilmaz, Jacopo M Fontana, Luigi Vignali, Chiara Boiocchi, Ilaria Sbarsi, Mariaclara Cuccia |
Journal | Archives of medical research
(Arch Med Res)
Vol. 39
Issue 3
Pg. 320-5
(Apr 2008)
ISSN: 0188-4409 [Print] United States |
PMID | 18279705
(Publication Type: Journal Article)
|
Chemical References |
- Genetic Markers
- Glycation End Products, Advanced
- Adenine
- Thymidine
|
Topics |
- Adenine
(metabolism)
- Coronary Artery Disease
(epidemiology, genetics)
- Diabetes Mellitus
(epidemiology, genetics)
- Female
- Follow-Up Studies
- Genetic Markers
(genetics)
- Glycation End Products, Advanced
(genetics)
- Humans
- Male
- Middle Aged
- Polymorphism, Genetic
(genetics)
- Risk Factors
- Thymidine
(genetics)
|